Safety and efficacy of atovaquone and proguanil hydrochloride for the prophylaxis of Plasmodium falciparum malaria in South Africa

Clinical Therapeutics

Volumn 21, Issue 4, 1999, Pages 741-749

  Dirk van der Berg, J ^a   Duvenage, Cornelia S J ^a   Roskell, Neil S ^b   Scott, Trevor R ^c  

^a 1 Military Hospital   (South Africa)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Atovaquone; Malaria; Malarone(TM); Plasmodium falciparum; Proguanil

Indexed keywords

ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; DOXYCYCLINE; MEFLOQUINE; QUININE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BLOOD SMEAR; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MALARIA; MALARIA CONTROL; MALE; NAUSEA; NORMAL HUMAN; PATIENT COMPLIANCE; PLASMODIUM FALCIPARUM; SKIN DISEASE; TREATMENT OUTCOME; VERTIGO;

EID: 0032975826     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88325-3     Document Type: Article

References (33)

1. Olliaro P, Cattani J, Wirth D. Malaria, the submerged disease. JAMA. 1996;275:230-233.
2. World Health Organization. World malaria situation in 1992. Wkly Epidemiol Rec. 1994;69:309-316.
3. Croft A, Garner P. Mefloquine to prevent malaria: A systematic review of trials. BMJ. 1997;315:1412-1416.
4. Hoffman SL. Diagnosis, treatment, and prevention of malaria. Med Clin North Am. 1992;76:1327-1355.
5. Zucker JR, Barber AM, Paxton LA, et al. Malaria surveillance - United States, 1992. MMWR Morb Mortal Wkly Rep. 1995;44(SS-5):1-15.
6. Bjorkman A, Phillips-Howard PA. The epidemiology of drug-resistant malaria. Trans R Soc Trop Med Hyg. 1990;84:177-180.
7. Wernsdorfer WH. Epidemiology of drug resistance in malaria. Acta Trop. 1994;56: 143-156.
8. White NJ. Antimalarial drug resistance: The pace quickens. J Antimicrob Chemother. 1992;30:571-585.
9. White NJ. The treatment of malaria. NEJM. 1996:335:800-806.
10. World Health Organization. Practical chemotherapy of malaria. World Health Organization Tech Rep Ser. 1990;805: 1-141.
11. Cook IF, Kish MY. Haematological safely of long-term malarial prophylaxis with dapsone-pyrimethamine. Med J Aust. 1985;143:129-141.
12. Hatton CSR, Peto TEA, Bunch C, et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet. 1986;1:411-414.
13. Hellgren U, Rombo L, Berg B. Adverse reactions to sulphadoxine/pyrimethamine in Swedish travellers: Implications for prophylaxis. BMJ. 1987;295:365-366.
14. Keystone JS. Prevention of malaria. Drugs. 1990;39:337-354.
15. Krogstad DJ, Herwaldt BL. Chemoprophylaxis and treatment of malaria. NEJM. 1988;319:1538-1540.
16. Larrey D, Castot A, Pessayre D, et al. Amodiaquine-induced hepatitis: A report of seven cases. Ann Intern Med. 1986; 104:801-803.
17. Panisko DM, Keystone JS. Treatment of malaria - 1990. Drugs. 1990;39:160-189.
18. Salako LA. Toxicity and side-effects of anti-malarials in Africa: A critical review. Bull WHO. 1984;62(Suppl):63-68.
19. Stuiver PC, Ligthelm RJ, Goud ThJLM. Acute psychosis after mefloquine. Lancet. 1989;2:282. Letter.
20. Taylor D, Pitarangsi C, Echeverria P, et al. Campylobacter enteritis during doxycycline prophylaxis for malaria in Thailand. Lancet. 1988;2:578-579.
21. Hudson AT, Dickins M, Ginger CD, et al. A potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs Exp Clin Res. 1991;17:427-435.
22. Fry M, Pudney M. Site of action of the antimalarial hydroxynaphthoquinone, 2-{trans-4-(4'-chlorphenyl) cyclohexyl}-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol. 1992;43:1545-1553.
23. Hammond DJ, Burchell JR, Pudney M. Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro. Mol Biochem Parasitol. 1985;14:97-109.
24. Srivastava IK, Rottenberg H, Vaidya AB. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem. 1997;272:3961-3966.
25. Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB. Malarone (atovaquone hydrochloride): A review of its clinical development for treatment of malaria. Am J Trop Med Hyg. 1999;60:533-541.
26. Shanks CD, Gordon DM, Klotz FW, et al. Efficacy and safety of atovaquone/proguanil for suppressive prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis. 1998;27:494-499.
27. Lell B, Luckner D, Ndjave M, et al. Randomized placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet. 1998;351: 709-713.
28. Sukwa TY, Mulenga M, Chisaka N, et al. A randomized, double blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria. Am J Trop Med Hyg. 1999;60:521-525.
29. Valecha N, Sharma VP, Devi CU. A rapid immunochromatographic test (ICT) for diagnosis of Plasmodium falciparum. Diagn Microbiol Infect Dis. 1998;30:257-260.
30. Haile LG, Flaherty JF. Atovaquone: A review. Ann Pharmacother. 1993;27:1488-1493.
31. Conover WJ. In: Practical Non-Parametric Statistics. New York: Wiley; 1980: 99-104.
32. Peto TEA, Newbold CI, Pasvol G. Qinghaosu, mefloquine, and pyrimethamine-sulfadoxine in falciparum malaria. Lancet. 1985;1:216. Letter.
33. Looareesuwan S, Viravan C, Webster HK, et al. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg. 1996;54:62-66.